Video

Dr. Thomas E. Hutson on results of phase 3 CLEAR trial of pembrolizumab/lenvatinib in RCC

Author(s):

Urology Times staff
Conference|GU Cancers Symposium

The immunotherapy/TKI combination significantly improved overall survival versus sunitinib.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected

      Thomas E. Hutson, DO, PharmD, Texas Oncology‐Baylor Charles A. Sammons Cancer Center, discusses findings from the phase 3 CLEAR trial, in which frontline therapy with pembrolizumab (Keytruda) plus lenvatinib (Lenvima) reduced the risk of death by 34% versus sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC). The combination also improved progression-free survival (PFS) and response compared with sunitinib. In the trial, it was also demonstrated that combining lenvatinib and everolimus improved PFS and objective response rate but not OS versus sunitinib in this setting (J Clin Oncol. 2021; 39[suppl6]:269. doi: 10.1200/JCO.2021.39.6_suppl.269).

      Related Videos
      Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
      Gopa Iyer, MD, highlights findings from FORAGER-1 in metastatic urothelial carcinoma
      Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
      Michael Schweizer, MD, shares data on mevrometostat plus enzalutamide in mCRPC
      Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer
      Nima Sharifi, MD, on the link between HSD3B1 and OS in prostate cancer
      Laura Bukavina, MD, highlights study of urinary microbiome profiling
      Laura Bukavina, MD, highlights study of urinary microbiome profiling
      Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
      Kate Gessner, MD, on the mechanisms of immunotherapy failure in RCC
      Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
      Darren Feldman, MD, on clinical outcomes in R/R testicular germ cell tumors
      ASCO GU recap: Insights on 5 key trials
      ASCO GU recap: Insights on 5 key trials
      Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
      Laurence Albiges, MD, on COSMIC-313 trial of triplet vs doublet combination in aRCC
      Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
      Francesca Jackson-Spence, MRCP, on efficacy of savolitinib/durvalumab in papillary renal cancer
      Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
      Gopa Iyer, MD, on durable efficacy of EV/pembrolizumab in urothelial carcinoma
      Related Content
      Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC
      March 4th 2025

      Adding 177Lu-PSMA-617 to enzalutamide extends OS in mCRPC

      Hannah Clarke
      The median OS was 34 months with 177Lu-PSMA-617 plus enzalutamide compared with 26 months with enzalutamide alone.
      Former MLB player Dave Winfield shares lessons from baseball, philanthropy
      November 15th 2024

      Former MLB player Dave Winfield shares lessons from baseball, philanthropy

      Urology Times staff
      In this episode of Speaking of Urology, former MLB player Dave Winfield shares lessons he’s learned throughout his professional baseball career and his work in philanthropy.
      CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC
      February 20th 2025

      CLEAR trial analyses reaffirm benefit of lenvatinib/pembrolizumab in aRCC

      Thomas E. Hutson, DO, PharmD
      "The updated results from CLEAR trial confirming that the amount of tumor shrinkage correlates with prognosis through overall survival, PFS, as well as through IMDC prognostic scoring should add further weight to lenvatinib and pembrolizumab being a go-to standard of care in this setting," says Thomas E. Hutson, DO, PharmD.
      blurred photo of a clinic hallway
      May 28th 2023

      2023 AUA highlights in benign urology

      Urology Times staff
      Gopal H. Badlani, MD, and Steven A. Kaplan, MD, discuss some of the notable abstracts in benign urology that were presented at the 2023 AUA Annual Meeting.
      Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC
      February 18th 2025

      Adding cabozantinib to nivolumab/ipilimumab confers PFS benefit in aRCC

      Hannah Clarke
      However, the triplet regimen did not lead to an improvement in overall survival.
      Human kidney cross section on science background. 3d render. | Image Credit: © Rasi - stock.adobe.com
      February 17th 2025

      Casdatifan is linked with promising safety, efficacy in clear cell RCC

      Benjamin P. Saylor
      “Over 80% of patients…had at least 2 lines of therapy, so this is a heavily refractory population,” said Toni K. Choueiri, MD, FASCO.
      © 2025 MJH Life Sciences

      All rights reserved.